SESSION TITLE: Pulmonary Vascular Disease II
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM
PURPOSE: Group II pulmonary hypertension is arises from increasing post-capillary pressures which may lead to pre-capillary remodeling. Clinical trials using medications developed for group I disease (PAH) have thus far yielded variable results. It has been proposed that this is, in part, due to inability to clearly identify those patients that would benefit from pulmonary vasodilator therapy. Morphologic changes such as pruning and proximal dilation have been described from CT scans and pulmonary angiography of patients with pulmonary hypertension both in PAH as well as group II disease. The differential arterial versus venous presence of these changes has not been previously quantified.